CORMORANT ASSET MANAGEMENT LP
Q1 2023 Form 13-F
BOSTON, MASSACHUSETTS
CIK 0001583977
· CRD 167820
· SEC-registered investment adviser
Consolidated report · includes
1 manager
since Q4 2013
$1.5B Reported Value Total
CORMORANT ASSET MANAGEMENT, LP reports 12 total accounts under management (AUM). There are 12 discretionary accounts valued at $3,117,053,633, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
7 funds
· $3.8B gross asset value
Hedge Fund: $2.2B · Private Equity Fund: $1.6B
Source: Form ADV filed 2026-05-27
Reported value
$1.5B
Quarter over quarter
+3.6%
Holdings
72
Top-10 concentration
56.1%
Filing Structure
Reports holdings for
- Chen Bihua · File #028-15950 · since Q4 2013
Key People
Form ADV owners & control persons
Bihua Chen
MANAGING MEMBER & CHIEF EXECUTIVE OFFICER
Nebojsa Obradovic
CHIEF COMPLIANCE OFFICER & GENERAL COUNSEL
Caleb Jonathan Tripp
CHIEF FINANCIAL OFFICER & CHIEF OPERATING OFFICER
Filing Navigation
13F Metrics
Loading 13F Metrics
Q1 2023 13F record
Q1 2023 13F filing summary
| Period of report | March 31, 2023 |
|---|---|
| Filed | May 15, 2023 |
| Form | 13F-HR |
| Reported value | $1.5B |
| Positions | 72 |
| Change in reported value | +1.6% |
| New positions | 12 |
| Exited positions | 12 |
| Position turnover | 28.6% |
| Top-10 concentration | 56.1% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2026 13F
Filed Aug 14, 2026
|
50 | $2.0B |
|
Q1 2026 13F
Filed May 15, 2026
|
46 | $2.0B |
|
Q4 2025 13F
Filed Feb 17, 2026
|
32 | $2.2B |
|
Q3 2025 13F
Filed Nov 14, 2025
|
36 | $1.4B |
|
Q2 2025 13F
Filed Aug 14, 2025
|
42 | $1.3B |
|
Q1 2025 13F
Filed May 15, 2025
|
42 | $1.3B |
|
Q4 2024 13F
Filed Feb 14, 2025
|
48 | $1.8B |
|
Q3 2024 13F
Filed Nov 14, 2024
|
45 | $1.9B |
|
Q2 2024 13F
Filed Aug 14, 2024
|
47 | $1.7B |
|
Q1 2024 13F
Filed May 15, 2024
|
56 | $2.3B |
|
Q4 2023 13F
Filed Feb 14, 2024
|
47 | $2.1B |
|
Q3 2023 13F
Filed Nov 14, 2023
|
49 | $1.7B |
|
Q2 2023 13F
Filed Aug 14, 2023
|
61 | $1.8B |
|
Q1 2023 13F
Filed May 15, 2023
|
72 | $1.5B |
|
Q4 2022 13F
Filed Feb 14, 2023
|
72 | $1.5B |
|
Q3 2022 13F
Filed Nov 14, 2022
|
72 | $1.4B |
|
Q2 2022 13F
Filed Aug 15, 2022
|
79 | $1.3B |
|
Q1 2022 13F
Filed May 16, 2022
|
77 | $1.3B |
|
Q4 2021 13F
Filed Feb 14, 2022
|
78 | $1.7B |
|
Q3 2021 13F
Filed Nov 15, 2021
|
88 | $2.5B |
31 earlier quarters on file — choose one from the quarter menu above.
Top 20 holdings · Q1 2023
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | RXDX PROMETHEUS BIOSCIENCES INC | $177.6M | 11.7% |
| 2 | MLTX MOONLAKE IMMUNOTHERAPEUTICS | $147.4M | 9.71% |
| 3 | BMEA BIOMEA FUSION INC | $110.7M | 7.29% |
| 4 | APLS APELLIS PHARMACEUTICALS INC | $89.7M | 5.91% |
| 5 | AMAM AMBRX BIOPHARMA INC | $75.8M | 4.99% |
| 6 | BBIO BRIDGEBIO PHARMA INC | $75.6M | 4.98% |
| 7 | ACLX ARCELLX INC | $49.3M | 3.25% |
| 8 | ETNB 89BIO INC | $42.6M | 2.81% |
| 9 | ELVN ENLIVEN THERAPEUTICS INC | $42.4M | 2.79% |
| 10 | RNA AVIDITY BIOSCIENCES INC | $40.1M | 2.64% |
| 11 | PTGX PROTAGONIST THERAPEUTICS INC | $39.1M | 2.58% |
| 12 | PLRX PLIANT THERAPEUTICS INC | $38.4M | 2.53% |
| 13 | ERAS ERASCA INC | $32.5M | 2.14% |
| 14 | AVTE AEROVATE THERAPEUTICS INC | $31.5M | 2.07% |
| 15 | DSGN DESIGN THERAPEUTICS INC | $29.7M | 1.96% |
| 16 | RAIN RAIN ONCOLOGY INC | $26.0M | 1.71% |
| 17 | IMRX IMMUNEERING CORP | $23.2M | 1.53% |
| 18 | GLUE MONTE ROSA THERAPEUTICS INC | $22.5M | 1.48% |
| 19 | VRDN VIRIDIAN THERAPEUTICS INC | $21.6M | 1.42% |
| 20 | VECT VECTIVBIO HLDG AG | $21.6M | 1.42% |
Values as reported on the Q1 2023 Form 13F. Every position is in the holdings table below.